Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LEVONEST vs ALYACEN 7/7/7
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Levonorgestrel is a synthetic progestin that inhibits ovulation by suppressing luteinizing hormone (LH) surge, alters cervical mucus to impede sperm penetration, and induces endometrial changes that inhibit implantation.
Combination of norethindrone (progestin) and ethinyl estradiol (estrogen) that inhibits gonadotropin release from the pituitary, suppressing ovulation, increasing cervical mucus viscosity, and altering endometrial receptivity.
Emergency contraception (FDA-approved),Contraception (as a progestin-only pill or in combination with estrogen),Off-label: treatment of menorrhagia, endometriosis, and as a component of hormone replacement therapy
Prevention of pregnancy
One tablet (levonorgestrel 1.5 mg) orally as a single dose within 72 hours of unprotected intercourse.
ALYACEN 7/7/7 is a combination oral contraceptive containing ethinyl estradiol 0.02 mg and drospirenone 3 mg. One tablet taken orally once daily for 28 days (7 active, 7 placebo, 7 active) without a hormone-free interval.
The terminal elimination half-life is approximately 24-30 hours. This relatively long half-life supports once-daily dosing and allows for stable plasma concentrations within 5-7 days of continuous use.
Terminal elimination half-life is 14 hours (range 12-16 h) in healthy adults; prolonged to 24-30 h in moderate renal impairment (Cr Cl 30-50 m L/min).
Primarily hepatic via CYP3A4; undergoes reduction and conjugation; excreted in urine and feces.
Norethindrone: primarily hepatic via reduction and conjugation, with CYP3A4 involvement. Ethinyl estradiol: primarily via CYP3A4, also undergoes sulfation and glucuronidation.
Renal excretion of conjugated metabolites accounts for approximately 60-80% of an administered dose; fecal elimination via bile accounts for 20-40%.
Renal: ~50% (unchanged drug); Fecal: ~20% (via bile); Biliary: ~30% (metabolites). Total clearance is 12 L/h.
Levonorgestrel is extensively bound to sex hormone-binding globulin (SHBG) and albumin; approximately 97-99% bound, with the free fraction being pharmacologically active.
98% bound primarily to albumin; minor binding to alpha-1-acid glycoprotein.
Apparent volume of distribution is about 1.8 L/kg, indicating extensive distribution into tissues beyond plasma water.
0.35 L/kg (total body water distribution); in obesity, Vd increases to 0.5 L/kg due to lipophilicity.
Oral bioavailability is approximately 100% due to minimal first-pass metabolism; levonorgestrel is completely absorbed after oral administration.
Oral: 85% (with high-fat meal reduces to 70%); Sublingual: 90%.
No dosage adjustment required for any degree of renal impairment.
Contraindicated in patients with severe renal impairment (Cr Cl <30 m L/min) or acute renal failure due to drospirenone's antimineralocorticoid activity. No dose adjustment recommended for mild to moderate impairment (Cr Cl ≥30 m L/min).
Contraindicated in severe hepatic impairment (Child-Pugh class C). For mild to moderate impairment, no specific dose adjustment available; use with caution.
Contraindicated in patients with acute hepatic disease, hepatic tumors, or impaired liver function (Child-Pugh class B or C). Discontinue if jaundice or pruritus develops. No dose adjustment for Child-Pugh class A.
Weight ≥ 75 kg: single dose of levonorgestrel 1.5 mg orally. Weight < 75 kg: single dose of 1.5 mg is also used, but efficacy may be reduced; consider alternative methods.
Not indicated for use in pediatric patients before menarche. Safety and efficacy in postmenarchal adolescents are expected to be similar to adults; dose is same as adults.
Not indicated for postmenopausal women; no specific dose adjustment established for elderly.
Not indicated for use in postmenopausal women. No recommendations for geriatric population due to lack of indication.
None.
Cigarette smoking increases risk of serious cardiovascular events from combined oral contraceptives (COCs). Risk increases with age and amount smoked (especially >15 cigarettes/day). Women over 35 who smoke should not use COCs.
Do not use as regular contraceptive if multiple doses are taken in one cycle,Ectopic pregnancy risk reduced but not eliminated,Menstrual irregularities,Rare cases of hepatic adenoma or thromboembolic events,Use with caution in patients with severe hepatic impairment or malabsorption syndromes
Thrombotic disorders (thrombophlebitis, pulmonary embolism, cerebral hemorrhage, myocardial infarction),Cerebrovascular disease,Carcinoma of the breast or reproductive organs,Hepatic adenoma or carcinoma,Ocular lesions (retinal thrombosis, papilledema),Gallbladder disease,Carbohydrate/lipid effects,Elevated blood pressure,Hereditary angioedema,Chloasma,Hepatic impairment
Known or suspected pregnancy,Hypersensitivity to levonorgestrel or any component
Breast cancer (current or history),Undiagnosed abnormal genital bleeding,Known or suspected pregnancy,Current or history of thrombotic disorders (DVT, PE, stroke, MI),Cerebrovascular or coronary artery disease,Valvular heart disease with complications,Severe hypertension,Diabetes with vascular disease,Headaches with focal neurological symptoms (e.g., migraine with aura),Major surgery with prolonged immobilization,Known thrombophilia (e.g., Factor V Leiden, prothrombin mutation, protein S/C deficiency),Active liver disease (tumors, hepatitis, cirrhosis),Uncontrolled hypertension,Smoking (if age >35),Hypersensitivity to any component
No clinically significant food interactions. Levonest releases levonorgestrel locally in the uterus, and systemic absorption is minimal. No dietary restrictions required.
Grapefruit and grapefruit juice may increase ethinyl estradiol levels, potentially increasing side effects. St. John's wort (herbal supplement) can reduce contraceptive efficacy. No other significant food interactions; however, maintaining a stable intake of vitamin C and folate is generally recommended.
LEVONEST (levonorgestrel) is associated with minimal teratogenic risk if inadvertently used during pregnancy. First trimester: No increased risk of major malformations based on epidemiologic data. Second/third trimester: No known adverse fetal effects from occasional use; no evidence of fetotoxicity or teratogenicity from clinical studies. However, as a progestin-only contraceptive, it is not indicated during pregnancy.
ALYACEN 7/7/7 contains ethinylestradiol and norethindrone. First trimester: No increased risk of major birth defects based on epidemiologic studies; however, inadvertent use does not warrant termination. Second and third trimesters: Avoid use due to potential adverse effects on fetal development, including feminization of male fetuses and potential for congenital anomalies from progestin. Postnatal: Possible long-term effects on reproductive development.
Levonorgestrel is excreted into breast milk in small amounts (estimated infant dose <0.1% of maternal dose). M/P ratio not established. No adverse effects reported in breastfed infants with short-term use. The WHO considers it compatible with breastfeeding. Caution with prolonged use may reduce milk supply.
Contraindicated in breastfeeding. Ethinylestradiol reduces milk quantity and quality. Norethindrone is excreted in low amounts (M/P ratio approximately 0.3-0.4). However, combination oral contraceptives are not recommended during lactation due to estrogen effects on milk production.
No dosing adjustments are applicable as LEVONEST is contraindicated in pregnancy. Pharmacokinetic changes in pregnancy do not require dose modifications because the drug should not be used during pregnancy.
ALYACEN 7/7/7 is contraindicated in pregnancy; no dose adjustments are applicable as use is not recommended. Pharmacokinetic changes in pregnancy (increased clearance of steroids) would theoretically require higher doses, but due to fetal risks, alternative therapies should be used.
Levonest (levonorgestrel-releasing intrauterine system) provides effective contraception for up to 5 years. It can be used for emergency contraception if inserted within 5 days of unprotected intercourse. May reduce menstrual bleeding and dysmenorrhea. Expulsion risk is highest in first year, especially right after insertion. Check strings after each period. Contraindicated in acute pelvic inflammatory disease, postpartum endometritis, infected abortion, or untreated cervical infection.
ALYACEN 7/7/7 is a triphasic oral contraceptive containing ethinyl estradiol and norgestimate. The 7/7/7 regimen refers to the varying doses of norgestimate across three 7-day phases (0.18 mg, 0.215 mg, 0.25 mg) with a fixed 0.025 mg ethinyl estradiol. Use consistent 7-day placebo interval. Consider increased risk of venous thromboembolism (VTE) in patients with BMI >30, smoking >15 cigarettes/day, or age >35. Monitor for breakthrough bleeding, especially during the first 3 cycles. Avoid in patients with migraine with aura, uncontrolled hypertension, or history of DVT/PE. Drug interactions with CYP3A4 inducers (e.g., rifampin, carbamazepine) may reduce efficacy; consider backup contraception.
Levonest is a small T-shaped device placed in your uterus that releases a hormone to prevent pregnancy for up to 5 years.,You may have irregular bleeding or spotting for the first 3-6 months, which typically decreases over time.,Check the strings at the end of your period each month to ensure the device is in place.,Do not use Levonest if you think you might be pregnant, have a current pelvic infection, or have certain uterine abnormalities.,Most women can use Levonest safely; serious complications are rare but include perforation, expulsion, and infection.,Seek medical attention if you experience severe abdominal pain, fever, heavy bleeding, or missing strings.
Take one pill daily at the same time each day, in the order specified on the pack (active pills followed by placebo).,If you miss a pill, follow the package instructions; missing pills increases pregnancy risk, especially if placebo week is extended.,Common side effects include nausea, headache, breast tenderness, and spotting, which usually improve after 2-3 cycles.,Seek immediate medical attention for severe abdominal pain, chest pain, shortness of breath, leg pain/swelling, or severe headache.,This medication does not protect against HIV/AIDS or other sexually transmitted infections (STIs).,Inform your healthcare provider if you smoke, as smoking increases risk of serious cardiovascular side effects, especially if over 35 years.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LEVONEST vs ALYACEN 7/7/7, answered by our medical review team.
LEVONEST is a Oral Contraceptive that works by Levonorgestrel is a synthetic progestin that inhibits ovulation by suppressing luteinizing hormone (LH) surge, alters cervical mucus to impede sperm penetration, and induces endometrial changes that inhibit implantation.. ALYACEN 7/7/7 is a Oral Contraceptive that works by Combination of norethindrone (progestin) and ethinyl estradiol (estrogen) that inhibits gonadotropin release from the pituitary, suppressing ovulation, increasing cervical mucus viscosity, and altering endometrial receptivity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LEVONEST and ALYACEN 7/7/7 depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LEVONEST is: One tablet (levonorgestrel 1.5 mg) orally as a single dose within 72 hours of unprotected intercourse.. The standard adult dose of ALYACEN 7/7/7 is: ALYACEN 7/7/7 is a combination oral contraceptive containing ethinyl estradiol 0.02 mg and drospirenone 3 mg. One tablet taken orally once daily for 28 days (7 active, 7 placebo, 7 active) without a hormone-free interval.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LEVONEST and ALYACEN 7/7/7 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LEVONEST is classified as Category C. LEVONEST (levonorgestrel) is associated with minimal teratogenic risk if inadvertently used during pregnancy. First trimester: No increased risk of major malformations based on epi. ALYACEN 7/7/7 is classified as Category C. ALYACEN 7/7/7 contains ethinylestradiol and norethindrone. First trimester: No increased risk of major birth defects based on epidemiologic studies; however, inadvertent use does n. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.